Researchers at The University of Chicago Medical Center are conducting a study to evaluate the safety and effect of an intravenous study drug used in the treatment of patients with amyotrophic lateral sclerosis (ALS).

Participants will have safety laboratory tests throughout the study and their strength and vital capacity will be tested at regular intervals.

To be eligible to participate:

Participants MUST:

Have ALS;
Be at least 18 years old;
Be medically able to undergo the study procedures;
Have an FVC (forced vital capacity, a respiratory measurement) of at least 60 percent of normal;
Have a caregiver who will be available to help with daily study drug administration; and
Live within a reasonable distance of the Univ. of Chicago Medical Center, because of the need for frequent site visits.

Participants must NOT:

Be taking any other experimental drugs for ALS; and
Have a history of sensitivity to cephalosporin antibiotics (Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax and Fortaz are examples).

Contact Information:

For more information about this study, or to inquire about participating, please contact the Study Coordinator, Liz Shaviers at 773-702-6221 or by email at eshavier@neurology.bsd.uchicago.edu.

Researchers at the University of Chicago Medical Center are looking for individuals, 18 to 75 years of age, to participate in a research study of an experimental drug for diabetic peripheral neuropathy.

A screening visit will be conducted prior to enrollment into the study. All eligible subjects will undergo a physical and neurological examination, and an electrocardiogram (ECG) which looks at the electrical activity of your heart. You will also have blood and urine tests done. There is no charge for study related procedures and participants will be compensated for their time.

Return to the Research page
Learn more about our Clinical Trials